C-RAD appoints Linda Frölén as new CFO

MARKN.

C-RAD AB (publ), is announcing today that Linda Frölén has been appointed new Chief Financial Officer (CFO). She will take office latest September 30, 2024, and is replacing Jonas Reinhammar, Interim CFO since May 13, 2024.

Linda Frölén joins C-RAD from Sedana Medical AB (publ.), where she has served as Head of Group Finance since 2021. Her responsibilities have been to oversee the entire finance function. Previously, Linda has had multiple roles within Group finance, e g within life science company Meda AB (publ) and before that many years as auditor at Deloitte in Stockholm.
 
"We are thrilled to welcome Linda to C-RAD. Her extensive experience and broad expertise in financial management and accounting will be invaluable to us. I look forward to working together with Linda and am confident that she will bring significant value through her personality and professional skills." says Cecilia de Leeuw, CEO C-RAD and President.
 
“I am honored and happy to be part of the company in this important growth phase. I look forward working together with a strong and engaged team and to contribute to C-RAD’s successful development, continuing to establish C-RAD’s Surface Guided Radiation Therapy, SGRT, across more clinics and to improve the treatment and quality of life for cancer patients around the world – this feels important to me”, says Linda Frölén.
 
Linda holds a master's degree in business administration from the School of Business, Economics and Law at the University of Gothenburg, with specializations in accounting, corporate finance, and international macroeconomics.

Datum 2024-06-20, kl 16:15
Källa MFN
Kopiera toppinvesterare! Med eToros innovativa CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för att använda CopyTrader-funktionen.
Copy Trading innebär inte investeringsråd. Värdet på dina investeringar kan gå upp eller ned. Ditt kapital löper risk.